Sanofi (NYSE:SNY)‘s stock had its “market perform” rating reiterated by stock analysts at Sanford C. Bernstein in a note issued to investors on Thursday, The Fly reports. They presently have a $45.00 price target on the stock, down from their prior price target of $50.00. Sanford C. Bernstein’s price objective would suggest a potential upside of 15.44% from the stock’s current price.
A number of other equities research analysts have also recently commented on the company. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 6th. Morgan Stanley cut Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Thursday, December 14th. Barclays raised Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Finally, Nord/LB reaffirmed a “neutral” rating on shares of Sanofi in a research note on Wednesday, December 27th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $49.33.
Shares of Sanofi (SNY) traded down $0.52 during trading on Thursday, hitting $38.98. The company had a trading volume of 3,938,026 shares, compared to its average volume of 2,801,127. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26. Sanofi has a twelve month low of $38.14 and a twelve month high of $50.65. The firm has a market capitalization of $98,288.38, a PE ratio of 12.49, a PEG ratio of 2.25 and a beta of 0.85.
Large investors have recently bought and sold shares of the business. Fisher Asset Management LLC grew its stake in Sanofi by 3.3% in the third quarter. Fisher Asset Management LLC now owns 14,082,257 shares of the company’s stock valued at $701,156,000 after acquiring an additional 443,799 shares during the period. Parametric Portfolio Associates LLC grew its stake in Sanofi by 7.0% in the third quarter. Parametric Portfolio Associates LLC now owns 1,558,400 shares of the company’s stock valued at $77,593,000 after acquiring an additional 101,718 shares during the period. Baldwin Brothers Inc. MA grew its stake in Sanofi by 106.7% in the fourth quarter. Baldwin Brothers Inc. MA now owns 11,121 shares of the company’s stock valued at $478,000 after acquiring an additional 5,742 shares during the period. Beacon Financial Group grew its stake in Sanofi by 12.5% in the fourth quarter. Beacon Financial Group now owns 105,488 shares of the company’s stock valued at $4,536,000 after acquiring an additional 11,761 shares during the period. Finally, Argent Trust Co grew its stake in Sanofi by 32.0% in the third quarter. Argent Trust Co now owns 10,841 shares of the company’s stock valued at $540,000 after acquiring an additional 2,629 shares during the period. 9.09% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/11/sanofis-sny-market-perform-rating-reiterated-at-sanford-c-bernstein.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.